(Q39400111)

English

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study

scientific article published on January 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Hiromitsu Kumada

11

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Fumitaka Suzuki

3

object named as

Fumitaka Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

10

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Masahiro Kobayashi

7

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Yoshiyuki Suzuki

4

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1

object named as

Norio Akuta

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

9

object named as

Yasuji Arase

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

8

object named as

Satoshi Saitoh

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

6

object named as

Takashi Someya

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Akihito Tsubota

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Tetsuya Hosaka

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

38

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

91-97

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. The Study Group of Fulminant Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of lamivudine resistance by HBV

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic hepatitis B virus infection: treatment strategies for the next millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900335-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(02)00335-5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39400111&oldid=1825873124"